141 related articles for article (PubMed ID: 29304353)
1. Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes.
Cecchini M; Walther Z; Sklar JL; Bindra RS; Petrylak DP; Eder JP; Goldberg SB
Lancet Oncol; 2018 Jan; 19(1):23-24. PubMed ID: 29304353
[No Abstract] [Full Text] [Related]
2. Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer.
Lozano R; Castro E; Aragón IM; Cendón Y; Cattrini C; López-Casas PP; Olmos D
Br J Cancer; 2021 Feb; 124(3):552-563. PubMed ID: 33106584
[TBL] [Abstract][Full Text] [Related]
3. Olaparib Targets Some Advanced Prostate Cancers.
Cancer Discov; 2016 Jan; 6(1):OF1. PubMed ID: 26658963
[TBL] [Abstract][Full Text] [Related]
4. PARP Inhibitors in Prostate Cancer.
Grewal K; Grewal K; Tabbara IA
Anticancer Res; 2021 Feb; 41(2):551-556. PubMed ID: 33517260
[TBL] [Abstract][Full Text] [Related]
5. PARP inhibition in BRCA2-mutated prostate cancer.
Nientiedt C; Tolstov Y; Volckmar AL; Endris V; Bonekamp D; Haberkorn U; Jäger D; Sültmann H; Stenzinger A; Hohenfellner M; Grüllich C; Duensing S
Ann Oncol; 2017 Jan; 28(1):189-191. PubMed ID: 27687312
[No Abstract] [Full Text] [Related]
6. Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein.
Ghiringhelli F; Richard C; Chevrier S; Végran F; Boidot R
World J Gastroenterol; 2016 Dec; 22(48):10680-10686. PubMed ID: 28082821
[TBL] [Abstract][Full Text] [Related]
7. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.
Sandhu SK; Omlin A; Hylands L; Miranda S; Barber LJ; Riisnaes R; Reid AH; Attard G; Chen L; Kozarewa I; Gevensleben H; Campbell J; Fenwick K; Assiotis I; Olmos D; Yap TA; Fong P; Tunariu N; Koh D; Molife LR; Kaye S; Lord CJ; Ashworth A; de Bono J
Ann Oncol; 2013 May; 24(5):1416-8. PubMed ID: 23524863
[No Abstract] [Full Text] [Related]
8. PARP inhibitors for targeted treatment in ovarian cancer.
Dizon DS
Lancet; 2017 Oct; 390(10106):1929-1930. PubMed ID: 28916370
[No Abstract] [Full Text] [Related]
9. Olaparib provides benefit in metastatic breast cancer.
Das M
Lancet Oncol; 2017 Jul; 18(7):e376. PubMed ID: 28602780
[No Abstract] [Full Text] [Related]
10. Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure.
Necchi A; Raggi D; Giannatempo P; Alessi A; Serafini G; Colecchia M; Ali SM; Chung JH
Eur J Cancer; 2018 Jun; 96():128-130. PubMed ID: 29680362
[No Abstract] [Full Text] [Related]
11. Molecular stratification and repair defects: revealing hidden treasures.
Hutchinson L
Nat Rev Clin Oncol; 2015 Dec; 12(12):683. PubMed ID: 26573421
[No Abstract] [Full Text] [Related]
12. PARP inhibitors for ovarian cancer.
Med Lett Drugs Ther; 2017 Dec; 59(1535):200-202. PubMed ID: 29186085
[No Abstract] [Full Text] [Related]
13. Stratifying prostate patients for olaparib.
Cancer Discov; 2015 Jun; 5(6):568-9. PubMed ID: 25904654
[TBL] [Abstract][Full Text] [Related]
14. Third of men with treatment resistant prostate cancer respond to drug that targets gene defect, study finds.
Mayor S
BMJ; 2015 Oct; 351():h5783. PubMed ID: 26518710
[No Abstract] [Full Text] [Related]
15. A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.
Pratt G; Yap C; Oldreive C; Slade D; Bishop R; Griffiths M; Dyer MJS; Fegan C; Oscier D; Pettitt A; Matutes E; Devereux S; Allsup D; Bloor A; Hillmen P; Follows G; Rule S; Moss P; Stankovic T
Br J Haematol; 2018 Aug; 182(3):429-433. PubMed ID: 28643365
[No Abstract] [Full Text] [Related]
16. Moving Beyond the Androgen Receptor in Advanced Prostate Cancer Commentary on: DNA-repair Defects and Olaparib in Metastatic Prostate Cancer.
Chedgy EC; Black PC
Urology; 2016 Mar; 89():10-1. PubMed ID: 26723184
[No Abstract] [Full Text] [Related]
17. Defective DNA repair mechanisms in prostate cancer: impact of olaparib.
De Felice F; Tombolini V; Marampon F; Musella A; Marchetti C
Drug Des Devel Ther; 2017; 11():547-552. PubMed ID: 28280302
[TBL] [Abstract][Full Text] [Related]
18. The 4th European Society for Medical Oncology Asia Congress: bridging ultimate cancer care with real-world practice for the Asian practitioner in gynecological cancers.
Ngoi NY; Tan DS
J Gynecol Oncol; 2019 Mar; 30(2):e48. PubMed ID: 30740965
[No Abstract] [Full Text] [Related]
19. Durable response to olaparib in pancreatic duct adenocarcinoma with deleterious ARID1A mutation.
Zhao XS; Zhou J; Dong L; Zhang H; Ye YJ
Chin Med J (Engl); 2019 Dec; 132(24):3012-3014. PubMed ID: 31764178
[No Abstract] [Full Text] [Related]
20. [The PROfound study or the arrival of personalised medicine in the treatment of prostate cancer].
Houédé N
Bull Cancer; 2021 May; 108(5):448. PubMed ID: 33722378
[No Abstract] [Full Text] [Related]
[Next] [New Search]
